Business Wire

MA-VERISTAT

Share
Veristat Announces Global Cell and Gene Therapy Center of Excellence

Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat , a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.

“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”

Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:

  • The ability to develop your therapeutic with accelerated approval pathways and/or special designations
  • A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
  • Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
  • Expertise in logistics and handling of live cellular material
  • Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
  • Long-term follow-up strategies to meet global regulatory requirements

“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”

About Veristat:

Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/VeristatCRO/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku opens Rigaku Technology Center Taiwan20.10.2025 17:00:00 CEST | Press release

- Advancing regional growth through engineering and collaboration in Taiwan and beyond - Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/ Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region. RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The f

InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API20.10.2025 16:00:00 CEST | Press release

Collaboration Strengthens Interoperability and Enables Providers to Harness AI with Reliable Data Foundations InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications. The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform. “AI is transforming healthcare, but it can only succeed when it’s ground

Wolters Kluwer supports SOCAR’s digital transformation journey with launch of Enablon Control of Work solution at Pirallahi Island upstream facility20.10.2025 15:30:00 CEST | Press release

Wolters Kluwer today announced that the State Oil Company of the Azerbaijan Republic (SOCAR) has successfully launched the Enablon Control of Work (CoW) solution at its first upstream oil gathering location in the Abşeronneft Oil and Gas Production Department (OGPD), located on Pirallahi Island. In line with its digital transformation efforts, the company shifts from manual, paper-based systems to fully integrated digital workflows for managing work permits, isolations, risk assessments, and safety protocols. As the fully state-owned enterprise responsible for oil and natural gas production from both onshore and offshore fields in the Azerbaijani sector of the Caspian Sea, SOCAR plays a vital role in the nation’s energy infrastructure. It operates Azerbaijan’s only oil refinery, a gas processing plant, and oversees several strategic oil and gas export pipelines. With the rollout of the Enablon CoW solution, SOCAR is strengthening its commitment to standardizing safety practices across

TagEnergy Selects Sitetracker to Accelerate Renewable Energy Growth20.10.2025 15:00:00 CEST | Press release

Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that TagEnergy, a fast-growing renewable energy producer, has selected Sitetracker to standardize operations and scale its portfolio across multiple markets. The move underscores TagEnergy’s commitment to delivering clean energy projects more efficiently while maintaining the highest standards of quality and transparency. TagEnergy develops and operates wind, solar, and battery storage projects across Europe, Japan and Australia, and is on track to double its size in the next three to four years. To support this growth, the company required a modern, flexible platform to unify processes across departments and countries, eliminate reliance on spreadsheets, and provide real-time visibility into project performance. By deploying Sitetracker, TagEnergy will: Get more done faster by eliminating manual tasks, standardizing workflows, and enabling teams to manage more projects wi

Lenovo Advances the AI-Enabled Workforce with Agentic AI: Trusted, Proven, and Ready to Deliver ROI20.10.2025 15:00:00 CEST | Press release

IDC projects agentic AI to double workforce productivity by 2027, while generative AI is already delivering $4 in return for every $1 invested.Lenovo integrates new agentic AI capabilities across AI PCs, Services, and TruScale DaaS to boost productivity, protection, and enterprise efficiency. As enterprises race to capture value from AI, Lenovo today unveiled new agentic AI capabilities as the centerpiece of its AI-Enabled Workforce portfolio, a complete suite of devices, services, and lifecycle solutions that turn AI investments into measurable business value. According to IDC, enterprises are already realizing nearly $4 in return for every $1 invested in generative AI, and by 2027 agentic AI is expected to double workforce productivity worldwide1 – evidence that organizations are moving from AI experimentation to tangible results. This marks a turning point where enterprises are shifting from piloting AI to embedding intelligent automation across their workforces, and Lenovo is helpi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye